ID: ALA65078

Max Phase: Preclinical

Molecular Formula: C21H24Cl2N4

Molecular Weight: 403.36

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCN(CC1CC1)c1cc(C)nc2c(-c3ccc(Cl)cc3Cl)c(C)nn12

Standard InChI:  InChI=1S/C21H24Cl2N4/c1-4-9-26(12-15-5-6-15)19-10-13(2)24-21-20(14(3)25-27(19)21)17-8-7-16(22)11-18(17)23/h7-8,10-11,15H,4-6,9,12H2,1-3H3

Standard InChI Key:  MOFYZEYIRXKTQI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 403.36

Molecular Weight (Monoisotopic): 402.1378

AlogP: 5.95

#Rotatable Bonds: 6

Polar Surface Area: 33.43

Molecular Species: NEUTRAL

HBA: 4

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 2.09

CX LogP: 5.63

CX LogD: 5.63

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.51

Np Likeness Score: -1.67

References

1. Wustrow DJ, Capiris T, Rubin R, Knobelsdorf JA, Akunne H, Davis MD, MacKenzie R, Pugsley TA, Zoski KT, Heffner TG, Wise LD..  (1998)  Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.,  8  (16): [PMID:9873487] [10.1016/s0960-894x(98)00372-2]

2. Chen C, Wilcoxen KM, Huang CQ, McCarthy JR, Chen T, Grigoriadis DE..  (2004)  Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.,  14  (14): [PMID:15203140] [10.1016/j.bmcl.2004.05.019]

3. Chen C, Wilcoxen KM, Huang CQ, Xie YF, McCarthy JR, Webb TR, Zhu YF, Saunders J, Liu XJ, Chen TK, Bozigian H, Grigoriadis DE..  (2004)  Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.,  47  (18): [PMID:15341493] [10.1021/jm040058e]

4. Das B, Baidya ATK, Mathew AT, Yadav AK, Kumar R..  (2022)  Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,  56  [PMID:35033884] [10.1016/j.bmc.2022.116614]

Source

Source(1):

• Scientific Literature